How TNF Blockers Treat Illnesses/Conditions

The tumor necrosis factor (TNF) inhibitors/blockers are a group of drugs that commonly treat chronic inflammatory diseases such as rheumatoid arthritis (RA), according to the John Hopkins Medical Center. The drugs are also described as autoimmune disorder drugs and were first approved in 1998.

What Are TNF Inhibitors?

The Mayo Clinic describes TNF-alphas as cytokines or cell proteins. The TNF-alpha inhibitors act by blocking the cell protein, or cytokine, to decrease pain, stiffness or swollen joints of rheumatoid arthritis and other inflammatory conditions. There have been several TNF inhibitors that have been approved for manufacture and these include:

* etanercept (Enbrel)

* infliximab (Remicade)

* adalimumab (Humira)

* certolizumab pegol (Cimzia)

TNF inhibitors are known to treat the following conditions:

* Crohn’s disease, a gastrointestinal (GI) tract condition in which the small intestines and colon become inflamed

* Ankylosing spondylitis, also known as Bechterew’s disease or syndrome, causes inflammatory arthritis in the spine as well as in

sacroiliac joints and is considered extremely painful

* rheumatoid arthritis

* psoriatic arthritis, a disease that causes the skin and the joints to become inflamed

TNF Inhibitors Investigated for Side Effects

Recently, the U.S. Food and Drug Administration (FDA) announced that it had been investigating approximately 240 cases of histoplasmosis, 45 of which were fatal, and all were patients using TNF blockers, according to a Reuters news article. Histoplasmosis is a fungal infection with a wide variety of symptoms; however, it commonly affects the lungs, according to the Centers for Disease Control and Prevention (CDC). While the illness is not common and can often be treated with anti-fungal medicine, it can also become fatal among certain patients. The infection has become more common among individuals suffering from cancer, HIV/AIDS and other immunosuppressor conditions.

John Hopkins Medical Center reports additional side effects, which include:

* infection site reactions may occur although the reactions are described as mild and decrease with repeated doses, (including skin infections)

* infections in addition to histoplasmosis

* malignancy

* immunogenecity

The FDA has announced that based on its investigation, warning labels should be strengthened to warn physicians and patients of the infections that have been discovered among this family of drugs.

Seeking Legal Assistance for TNF Inhibitors Risks

Due to the recent controversy over the consumption of the TNF blockers and the alleged side effects, patients of these prescription drugs should consider contacting a pharmaceutical attorney for a free legal consultation on the developing a potential TNF inhibitor lawsuit.

One of the TNF blockers, Cimzia, has continued to remain in the news for its serious side effects not only related to infections but also for its potential link to causing cancer among young adult and children aged patients.

In addition to the FDA investigating the cancer risks posed by the TNF blockers, an investigation into the potential life-threatening fungal infections is also being pursued. Individuals who are taking Cimzia or any of the other TNF blockers and who fear they may be at risk for developing any of the side effects associated with these drugs should discontinue the drug immediately and seek a medical professional immediately. It is advisable for a victim of the Cimzia side effects to not only discuss their condition with a medical professional, but should also contact an experienced pharmaceutical attorney to learn about developing a Cimzia class action lawsuit.